Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars

Core Insights - Viatris Inc. has released positive data from a Phase 3 study on the contraceptive efficacy and safety of XULANE LO, a low-dose weekly dermal patch [1][2] - The company also reported results from a Phase 3 program for a fast-acting formulation of meloxicam, MR-107A-02, for moderate-to-severe acute pain [4][5] Contraceptive Study Findings - XULANE LO demonstrated a Pearl Index (PI) of 4.14, indicating contraceptive efficacy, with a cumulative probability of pregnancy over 13 cycles at 3.7% [2] - The safety profile was favorable, with most treatment-emergent adverse events reported as mild to moderate, and a low rate of unscheduled bleeding and spotting [2][3] - The patch adhesion profile was noted as best-in-class, with only 1.3% of patches completely detaching during the seven-day wear period [3] Pain Management Study Findings - MR-107A-02 showed statistically significant and clinically meaningful results in pain management following herniorrhaphy and bunionectomy surgeries [5][8] - The treatment led to a notable reduction in opioid usage, with 72.6% of patients opioid-free after herniorrhaphy compared to 58.6% in the placebo group, and 56.9% opioid-free after bunionectomy compared to 33.1% in the placebo group [8] Financial Performance - For Q1 2025, Viatris reported total revenues of $3.3 billion, down 11% year-over-year, primarily due to the negative Indore Impact [6][9] - The estimated Indore Impact on total revenues was approximately $140 million, with management projecting a revenue reduction of $500 million for 2025 due to issues at the Indore facility [7][9] - The company reaffirmed its 2025 sales outlook of $13.5 billion to $14 billion, with adjusted EPS guidance raised to $2.16-$2.30 [9][10] Stock Performance - Following the announcements, VTRS stock increased by 10.2%, reaching $9.48 [10]